Evidence map›Paper›PMID 42534559›Full record

ArticleFrontiers in microbiology2026

Investigation of pathogen resistance in Chinese cancer patients based on bacterial resistance surveillance in 23 provinces, 2016-2023.

Yingnan Ju, Kunbin Liu, Yu Xiao, Gang Ma, Biao Zhu, Hongzhi Wang, Zhenjie Hu, Jianghong Zhao, Li Zhang, Keliang Cui and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Yingnan Ju *Department of Critical Care Medicine, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Clinical College, Hainan, China.
Kunbin Liu *Department of Critical Care Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yu Xiao *Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Gang MaDepartment of Critical Care Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Biao ZhuDepartment of Critical Care Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Hongzhi WangDepartment of Critical Care Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Zhenjie HuDepartment of Critical Care Medicine, Hebei Tumor Hospital, Shijiazhuang, China.
Jianghong ZhaoDepartment of Critical Care Medicine, Hunan Cancer Hospital, Changsha, China.
Li ZhangDepartment of Critical Care Medicine, Hubei Cancer Hospital, Wuhan, China.
Keliang CuiDepartment of Critical Care Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Xin-Rong HeDepartment of Critical Care Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Mingguang HuangDepartment of Critical Care Medicine, Shanxi Cancer Hospital, Taiyuan, China.
Yang LiDepartment of Critical Care Medicine, Guangxi Medical University Cancer Hospital, Nanning, China.
Shanling XuDepartment of Critical Care Medicine, Sichuan Cancer Hospital, Chengdu, China.
Yuetian YuDepartment of Critical Care Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Yan GaoDepartment of Critical Care Medicine, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Kaizhong LiuDepartment of Critical Care Medicine, Zhejiang Cancer Hospital, Hangzhou, China.
Guoxing ZhangDepartment of Critical Care Medicine, Jilin Provincial Tumor Hospital, Changchun, China.
Haitao LiuDepartment of Critical Care Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Yong YeDepartment of Critical Care Medicine, Fujian Cancer Hospital, Fuzhou, China.
Linlin ZhangDepartment of Critical Care Medicine, Anhui Provincial Cancer Hospital, Hefei, China.
Xiangzhe ZhouDepartment of Critical Care Medicine, Gansu Provincial Cancer Hospital, Lanzhou, China.
Shuliang MaDepartment of Critical Care Medicine, Jiangsu Cancer Hospital, Nanjing, China.
Yu'an QiuDepartment of Critical Care Medicine, Jiangxi Cancer Hospital, Nanchang, China.
Ming ZhangDepartment of Critical Care Medicine, Hangzhou Cancer Hospital, Hangzhou, China.
Yong TaoDepartment of Critical Care Medicine, Nantong Tumor Hospital, Nantong, China.
Meiyun ZhangDepartment of Critical Care Medicine, Baotou Cancer Hospital, Baotou, China.
Lewu XianDepartment of Critical Care Medicine, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Wei XieDepartment of Critical Care Medicine, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.
Guang WangDepartment of Critical Care Medicine, The First Hospital of Jilin University, Changchun, China.
Yichun WangDepartment of Critical Care Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Changsong WangDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Donghao WangDepartment of Critical Care Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infection is a common and often fatal complication in cancer patients. Notably, cancer patients account for up to 21% of all sepsis cases. Furthermore, sepsis is present in 30% of all deaths among those hospitalized with cancer. However, comprehensive antimicrobial resistance (AMR) surveillance data specific to this population are lacking. This gap hinders the effectiveness of antimicrobial stewardship programs (ASPs). Methods: We investigated bacterial distribution and AMR patterns in Chinese cancer patients to inform empirical therapy and ASPs. This multicenter retrospective study collected hospital-wide clinical isolates and drug-susceptibility data from 23 cancer centers during 2016-2023. All procedures followed standardized methods in accordance with national surveillance protocols and Clinical and Laboratory Standards Institute guidelines. Data were subjected to dual validation using WHONET and a domestically developed big-data system. Results: Gram-negative 75.4% (270,609), Gram-positive 24.6% (88,177) of 358,786 isolates from cancer patients in these oncology centers. Predominant Gram-negative species were Conclusion: Carbapenem resistance among common Gram-negatives in cancer patients was below national averages. MRSA and enterococcal resistance were also below national levels. These findings underscore the unique resistance epidemiology in oncology, supporting tailored guidelines and dedicated surveillance.

Indexed as

antimicrobial stewardshipbacterial resistancecarbapenem resistanceGram-negative bacteriaGram-positive bacterialast-resort antibioticsmulticenter surveillancetumor

Identifiers

PMID42534559
PMCPMC13421402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.